Smoking cessation program and CYP2A6 polymorphism

Frontiers in Bioscience

Volumn 11, Issue SUPPL. 2, 2006, Pages 2590-2597

  Ozaki, Shinichi ^a,b   Oyama, Tsunehiro ^a,d   Isse, Toyohi ^a   Kagawa, Norio ^c   Uramoto, Hidetaka ^a   Sugio, Kenji ^a   Yasumoto, Kosei ^a   Kono, Keizo ^b   Kawamoto, Toshihiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b FUJI XEROX CO LTD   (Japan)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

And Smoking Cessation; CYP2A6; Nicotine Patch

Indexed keywords

EID: 33744532853     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1993     Document Type: Article

References (54)

1. Russell M. A., C. Feyerabend and P. V. Cole: Plasma nicotine levels after cigarette smoking and chewing nicotine gum. Br Med J 1(6017), 1043-1046 (1976)
2. Rahman S., J. Zhang and W. A. Corrigall: Effects of acute and chronic nicotine on somatodendritic dopamine release of the rat ventral tegmental area: in vivo microdialysis study. Neurosci Lett 348, 61-64 (2003)
3. Yoshimoto K., B. Kato, S. Ueda, K. Noritake, K. Sakai, M. Shibata, M. Hori, H. Kawano, Y. Takeuchi, Y. Wakabayashi and M. Yasuhara: Dopamine and serotonin uptake inhibitors on the release of dopamine and serotonin in the nucleus accumbens of young and aged rats. Mech Ageing Dev 122, 1707-1721 (2001)
4. Gerra G., S. Ceresini, A. Esposito, A. Zaimovic, G. Moi, M. Bussandri, M. A. Raggi and E. Molina: Neuroendocrine and behavioural responses to opioid receptor-antagonist during heroin detoxification: relationship with personality traits. Int Clin Psychopharmacol 18, 261-269 (2003)
5. Picciotto M. R. and W. A. Corrigall: Neuronal systems underlying behaviors related to nicotine addiction: neural circuits and molecular genetics. J Neurosci 22, 3338-3341 (2002)
6. Benowitz N. L., P. r. Jacob and D. P. Sachs: Deficient C-oxidation of nicotine. Clin Pharmacol Ther 57, 590-594 (1995)
7. Tyndale R. F. and E. M. Sellers: Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Ther Drug Monit 24, 163-171 (2002)
8. Oscarson M.: Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 29, 91-95 (2001)
9. Carter B., T. Long and P. Cinciripini: A meta-analytic review of the CYP2A6 genotype and smoking behavior. Nicotine Tob Res 6, 221-7 (2004)
10. Hadidi H., K. Zahlsen, J. R. Idle and S. Cholerton: A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem Toxicol 35, 903-907 (1997)
11. Yamano S., J. Tatsuno and F. J. Gonzalez: The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29, 1322-1329 (1990)
12. Fernandez-Salguero P. and F. J. Gonzalez: The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics 5 (Spec No), s123-s128 (1995)
13. Oscarson M., H. Gullsten, A. Rautio, M. L. Bernal, B. Sinues, M. L. Dahl, J. H. Stengard, O. Pelkonen, H. Raunio and M. Ingelman-Sundberg: Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett 438, 201-205 (1998)
14. Oscarson M., R. A. McLellan, H. Gullsten, Q. Y. Yue, M. A. Lang, M. L. Bernal, B. Sinues, A. Hirvonen, H. Raunio, O. Pelkonen and M. Ingelman-Sundberg: Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 448, 105-110 (1999)
15. Nunoya K. I., T. Yokoi, K. Kimura, T. Kainuma, K. Satoh, M. Kinoshita and T. Kamataki: A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans. J Pharmacol Exp Ther 289, 437-442 (1999)
16. Kitagawa K., N. Kunugita, M. Kitagawa and T. Kawamoto: CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J Biol Chem 276, 17830-17835 (2001)
17. Tyndale R. F. and E. M. Sellers: Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metab Dispos, 548-552 (2001)
18. Nakajima M., S. Yamagishi, H. Yamamoto, T. Yamamoto, Y. Kuroiwa and T. Yokoi: Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin Pharmacol Ther 67, 57-69 (2000)
19. Kitagawa K., N. Kunugita, T. Katoh, M. Yang and T. Kawamoto: The significance of the homozygous CYP2A6 deletion on nicotine metabolism: a new genotyping method of CYP2A6 using a single PCR-RFLP. Biochem Biophys Res Commun 262, 146-151 (1999)
20. Perera F. P.: Environment and cancer: who are susceptible? Science 278, 1068-1073 (1997)
21. Crespi C. L., B. W. Penman, H. V. Gelboin and F. J. Gonzalez: A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 12, 1197-1201 (1991)
22. Fujita K. and T. Kamataki: Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase. Environ Mol Mutagen 38, 339-346 (2001)
23. Oyama T., A. Matsumoto, T. Isse, Y. D. Kim, S. Ozaki, T. Osaki, K. Sugio, K. Yasumoto and T. Kawamoto: Evidence-based prevention (EBP): Approach to lung cancer prevention based on cytochrome 1A1 and cytochrome 2E1 polymorphism. Anticancer Res 23, 1731-1738 (2003)
24. London S. J., J. R. Idle, A. K. Daly and G. A. Coetzee: Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 353, 898-899 (1999)
25. Miyamoto M., Y. Umetsu, H. Dosaka-Akita, Y. Sawamura, J. Yokota, H. Kunitoh, N. Nemoto, K. Sato, N. Ariyoshi and T. Kamataki: CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem Biophys Res Commun 261, 658-660 (1999)
26. Loriot M. A., S. Rebuissou, M. Oscarson, S. Cenee, M. Miyamoto, N. Ariyoshi, T. Kamataki, D. Hemon, P. Beaune and I. Stacker: Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics 11, 39-44 (2001)
27. Ariyoshi N., M. Miyamoto, Y. Umetsu, H. Kunitoh, H. Dosaka-Akita, Y. Sawamura, J. Yokota, N. Nemoto, K. Sato and T. Kamataki: Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol Biomarkers Prev 11, 890-894 (2002)
28. Tan W., G. F. Chen, D. Y. Xing, C. Y. Song, F. F. Kadlubar and D. X. Lin: Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int J Cancer 95, 96-101 (2001)
29. Wang H., W. Tan, B. Hao, X. Miao, G. Zhou, F. He and D. Lin: Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 63, 8057-8061 (2003)
30. Fujieda M., H. Yamazaki, T. Saito, K. Kiyotani, M. A. Gyamfi, M. Sakurai, H. Dosaka-Akita, Y. Sawamura, J. Yokota, H. Kunitoh and T. Kamataki: Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers. Carcinogenesis in press (2004)
31. Peto R., A. D. Lopez, J. Boreham, M. Thun, C. J. Heath and R. Doll: Mortality from smoking worldwide. Br Med Bull 52, 12-21 (1996)
32. Vineis P, Airoldi L, Veglia P, Olgiati L, Pastorelli R, Autrup H, Dunning A, Garte S, Gormally E, Hainaut P, Malaveille C, Matullo G, Peluso M, Overvad K, Tjonneland A, Clavel-Chapelon F, Boeing H, Krogh V, Palli D, Panico S, Tumino R, Bueno-De-Mesquita B, Peeters P, Berglund G, Hallmans G, Saracci R and R. E.: Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. BMJ 330, 265-266 (2005)
33. Smedslund G., K. J. Fisher, S. M. Boles and E. Lichtenstein: The effectiveness of workplace smoking cessation programmes: a meta-analysis of recent studies. Tob Control 13, 197-204 (2004)
34. Oyama T., T. Kawamoto, T. Mizoue, K. Sugio, Y. Kodama, T. Mitsudomi and K. Yasumoto: Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res 17, 583-587 (1997)
35. Heatherton T. F., L. T. Kozlowski, R. C. Frecker and K. O. Fagerstrom: The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86 (1991)
36. Villanueva E. V. and S. Zavarsek: Evaluating heterogeneity in cumulative meta-analyses. BMC Med Res Methodol 4, 18 (2004)
37. Linard B., S. Bezieau, H. Benlalam, N. Labarriere, Y. Guilloux, E. Diez and F. Jotereau: A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol 168, 4802-4808 (2002)
38. Greer C. E., S. L. Peterson, N. B. Kiviat and M. M. Manos: PCR amplification from paraffin-embedded tissues. Effects of fixative and fixation time. Am J Clin Pathol 95, 117-124 (1991)
39. Hyland A., Q. Li, J. E. Bauer, G. A. Giovino, C. Steger and K. M. Cummings: Predictors of cessation in a cohort of current and former smokers followed over 13 years. Nicotine Tob Res 6 (Suppl 3), s363-s369 (2004)
40. Grotvedt L. and K. Stavem: Association between age, gender and reasons for smoking cessation. Scand J Public Health 33, 72-76 (2005)
41. Stead L. F., T. Lancaster and C. A. Silagy: Updating a systematic review-what difference did it make? Case study of nicotine replacement therapy. BMC Med Res Methodol 1, 10 (2001)
42. Silagy C., T. Lancaster, L. Stead, D. Mant and G. Fowler Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, CD000146 (2004)
43. Jarvis M. J.: Uptake of environmental tobacco smoke. IARC Sci Publ, 43-58 (1987)
44. Hughes J. R., S. T. Higgins and W. K. Bickel: Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction 89, 1461-1470 (1994)
45. Geller A.: Common addictions. Clin Symp 48, 2-32. (1996)
46. Dempsey D., P. Tutka, P. r. Jacob, F. Allen, K. Schoedel, R. F. Tyndale and N. L. Benowitz: Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 76, 64-72 (2004)
47. Pianezza M. L., Sellers E. M., and R. F. Tyndale: Nicotine metabolism defect reduces smoking. Nature 25, 393-395 (1998)
48. Gu D. F., L. J. Hinks, N. E. Morton and I. N. Day: The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 64, 383-390 (2000)
49. Schulz T. G., P. Ruhnau and E. Hallier: Lack of correlation between CYP2A6 genotype and smoking habits. Adv Exp Med Biol 500, 213-215 (2001)
50. Tiihonen J., U. Pesonen, J. Kauhanen, M. Koulu, T. Hallikainen, L. Leskinen and J. T. Salonen: CYP2A6 genotype and smoking. Mol Psychiatry 5, 347-348 (2000)
51. Yang M., N. Kunugita, K. Kitagawa, S. H. Kang, B. Coles, F. F. Kadlubar, T. Katoh, K. Matsuno and T. Kawamoto: Individual differences in urinary cotinine levels in Japanese smokers: relation to genetic polymorphism of drug-metabolizing enzymes. Cancer Epidemiol Biomarkers Prev 10, 589-593 (2001)
52. Zhang X., K. Amemo, S. Ameno, K. Iwahashi, H. Kinoshita, T. Kubota, J. Mostofa and I. Ijiri: Lack of association between smoking and CYP2A6 gene polymorphisms in Japanese population. Nihon Arukoru Yakubutsu Igakkai Zasshi 36, 486-490 (2001)
53. Pomerleau C. S., M. J. Majchrzak and O. F. Pomerleau: Nicotine dependence and the Fagerstrom Tolerance Questionnaire: a brief review. J Subst Abuse 1, 471-477 (1989)
54. Fagerstrom K. O. and N. G. Schneider: Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J Behav Med 12, 159-182 (1989)